From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics

SG Wicha, A.G. Märtson, E.I. Nielsen, B.C.P. Koch, L.E. Friberg, J.W. Alffenaar, I.K. Minichmayr
Clinical Pharmacology & Therapeutics, 109, 928-941 (2021).

Please login to see attachment

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

BT Tsuji, JM Pegue, AP Zavascki, M Paul, GL Daikos, A Forrest, DR Giacobbe, C Viscoli, H Giamarellou, I Karaiskos, D Kaye, JW Mouton, VH Tam, C Thamlikitkul, RG Wunderink, J Li, RL Nation, KS Kaye
Pharmacotherapy, 39, 10-39 (2019).

Please login to see attachment

Concentration-dependent plasma protein binding: Expect the unexpected

RL Nation, U Theuretzbacher, BT Tsuji, on behalf of the International Society of Anti-Infective Pharmacology (ISAP)
European Journal of Pharmaceutical Sciences, 122, 341-346 (2018).

Please login to see attachment

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus: RL Nation, J Li, O. Cars, W. Couet, MN Dudley, KS Kaye, JW Mouton, DL Paterson, VH Tam, U. Theuretzbacher, BT Tsuji, JD Turnidge.
The Lancet Infectious Diseases, Early Online Publication, 21 October 2014

Please login to see attachment

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

Jason A Roberts, Mohd H Abdul-Aziz, Jeff rey Lipman, Johan W Mouton, Alexander A Vinks, Timothy W Felton, William W Hope, Andras Farkas, Michael N Neely, Jerome J Schentag, George Drusano, Otto R Frey, Ursula Theuretzbacher, Joseph L Kuti, on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases

Lancet Infect Dis April 2014
Please login to see attachment

Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Gonzalez D, Schmidt S, Derendorf H.
Clin Microbiol Rev. 2013 Apr;26(2):274-88.

Please login to see attachment

New EMA guideline for antimicrobial development.

Ambrose PG, Bhavnani SM, Dudley MN, Ellis-Grosse E, Rubino CM, Drusano GL.
Lancet Infect Dis. 2012 Apr;12(4):265-6.

Please login to see attachment

Saving Lives with Optimal Antimicrobial Chemotherapy

Drusano GL, Lodise TP
Clin Infect Dis 2012 Oct 16

Please login to see attachment

Predicting bacterial fitness cost associated with drug resistance.

Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VH.
J Antimicrob Chemother. 2012 Apr;67(4):928-32.

Fundamentals of Population Pharmacokinetic Modelling: Modelling and Software.

Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH.
Clin Pharmacokinet. 2012 Aug 1;51(8):515-25.